| Dr Scott E Lamb, MD | |
|
600 Orondo Ave, Ste 1, Wenatchee, WA 98801-2800 | |
| (509) 662-6000 | |
| (509) 664-4588 |
| Full Name | Dr Scott E Lamb |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 600 Orondo Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093079949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD60540477 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lourdes Medical Center | Pasco, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Emergency Physicians Llc | 3476462334 | 186 |
News Archive
A new study published in the March 2020 issue of the journal Experimental Results reports that based on data from over 6,500 subjects, the commonly used AQ10 test is not relevant in diagnosing autism. That means a re-examination of the approach used at present to pick up this condition in the population at large is needed. It also means there is a question mark on the validity of research based on this test.
The Sixty-fifth World Health Assembly concluded Saturday after adopting 21 resolutions and three decisions on a broad range of health issues. The six days of discussions involved nearly 3000 delegates, including health ministers and senior health officials from amongst the 194 WHO Member States, as well as representatives from civil society and other stakeholders.
Latinos may be more anxious than Caucasian patients about having surgery and also want more detailed information before having a procedure, suggests research being presented at the ANESTHESIOLOGY 2016 annual meeting.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
› Verified 7 days ago
| Entity Name | Northwest Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235172370 PECOS PAC ID: 3476462334 Enrollment ID: O20041214000892 |
News Archive
A new study published in the March 2020 issue of the journal Experimental Results reports that based on data from over 6,500 subjects, the commonly used AQ10 test is not relevant in diagnosing autism. That means a re-examination of the approach used at present to pick up this condition in the population at large is needed. It also means there is a question mark on the validity of research based on this test.
The Sixty-fifth World Health Assembly concluded Saturday after adopting 21 resolutions and three decisions on a broad range of health issues. The six days of discussions involved nearly 3000 delegates, including health ministers and senior health officials from amongst the 194 WHO Member States, as well as representatives from civil society and other stakeholders.
Latinos may be more anxious than Caucasian patients about having surgery and also want more detailed information before having a procedure, suggests research being presented at the ANESTHESIOLOGY 2016 annual meeting.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
› Verified 7 days ago
| Entity Name | Lourdes Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659861060 PECOS PAC ID: 1850642562 Enrollment ID: O20181113000853 |
News Archive
A new study published in the March 2020 issue of the journal Experimental Results reports that based on data from over 6,500 subjects, the commonly used AQ10 test is not relevant in diagnosing autism. That means a re-examination of the approach used at present to pick up this condition in the population at large is needed. It also means there is a question mark on the validity of research based on this test.
The Sixty-fifth World Health Assembly concluded Saturday after adopting 21 resolutions and three decisions on a broad range of health issues. The six days of discussions involved nearly 3000 delegates, including health ministers and senior health officials from amongst the 194 WHO Member States, as well as representatives from civil society and other stakeholders.
Latinos may be more anxious than Caucasian patients about having surgery and also want more detailed information before having a procedure, suggests research being presented at the ANESTHESIOLOGY 2016 annual meeting.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Scott E Lamb, MD 600 Orondo Ave, Ste 1, Wenatchee, WA 98801-2800 Ph: (509) 662-6000 | Dr Scott E Lamb, MD 600 Orondo Ave, Ste 1, Wenatchee, WA 98801-2800 Ph: (509) 662-6000 |
News Archive
A new study published in the March 2020 issue of the journal Experimental Results reports that based on data from over 6,500 subjects, the commonly used AQ10 test is not relevant in diagnosing autism. That means a re-examination of the approach used at present to pick up this condition in the population at large is needed. It also means there is a question mark on the validity of research based on this test.
The Sixty-fifth World Health Assembly concluded Saturday after adopting 21 resolutions and three decisions on a broad range of health issues. The six days of discussions involved nearly 3000 delegates, including health ministers and senior health officials from amongst the 194 WHO Member States, as well as representatives from civil society and other stakeholders.
Latinos may be more anxious than Caucasian patients about having surgery and also want more detailed information before having a procedure, suggests research being presented at the ANESTHESIOLOGY 2016 annual meeting.
The PETA International Science Consortium's nanotechnology expert will present a poster titled "A Tiered-Testing Strategy for Nanomaterial Hazard Assessment" at the Topical Scientific Workshop – Regulatory Challenges in Risk Assessment of Nanomaterials being organized by the European Chemicals Agency (ECHA) on October 23 and 24 in Helsinki.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.
› Verified 7 days ago
Andrew G Eichler, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 707 N Emerson Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Carolyn R Johnson, ARNP Family Medicine Medicare: Medicare Enrolled Practice Location: 600 Orondo Ave, Ste 1, Wenatchee, WA 98801 Phone: 509-662-6000 Fax: 509-664-4588 | |
Richard J Beukema, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Orondo Ave 1, Wenatchee, WA 98801 Phone: 509-662-6000 Fax: 509-664-4590 | |
Donald R Murphy, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Patricia Ortiz, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Sara J. Norris, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 Orondo Ave, Wenatchee, WA 98801 Phone: 509-662-6000 |